照護現場感染疾病診斷的全球市場

到 2030 年，全球照護現場感染疾病診斷市場預計將達到 53 億美元

全球照護現場感染疾病診斷市場預計 2023 年為 26 億美元，預計到 2030 年將達到 53 億美元，2023-2030 年分析期間複合年成長率為 10.8%。側流免疫檢測是本報告分析的細分市場之一，預計複合年成長率為 11.6%，到分析期結束時將達到 27 億美元。分析期內，流通式測試領域的複合年成長率預計為10.6%。

美國市場預估為7.113億美元，中國預期複合年成長率為14.8%

到 2023 年，美國照護現場感染疾病診斷市場預計將達到 7.113 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達12億美元，2023-2030年分析期間複合年成長率為14.8%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 8.0% 和 9.3%。在歐洲，德國預計複合年成長率為 8.5%。

全球照護現場感染疾病診斷市場—主要趨勢與促進因素總結

為什麼照護現場感染疾病診斷將改變醫療保健服務和病患治療結果。

照護現場(POC)感染疾病診斷透過在患者照護點或附近對感染疾病進行快速、準確和分散式檢查，正在徹底改變醫療保健。這些診斷包括各種測試，例如橫向流動化驗、快速抗原測試、分子診斷測定和免疫測量，並且可以在傳統實驗室之外進行，使醫療保健專業人員能夠及時獲得重要資訊。與需要密集實驗室、專業設備和長時間測試的傳統診斷方法不同，POC 診斷方法可以在幾分鐘到幾小時內提供結果，從而可以立即診斷並開始治療。這種快速檢測能力對於愛滋病毒、結核病、流感和性行為感染感染（STI）等感染疾病的管理尤其重要，早期發現和及時治療對於減少疾病傳播並改善患者治療效果極為重要。

POC感染疾病診斷方法擴大被採用，是因為它們能夠改善檢測的機會，特別是在偏遠、資源有限和服務不足的地區。這些診斷不需要複雜的測試基礎設施，允許在農村診所、社區健康中心甚至患者家用中進行測試。這種可近性對於應對全球健康挑戰至關重要，特別是在醫療保健資源有限和感染疾病負擔較高的低收入和中等收入國家。此外，POC 診斷的便利性和易用性提高了患者的依從性並減少了後續觀察的需要，從而支持更有效率的醫療服務並減輕醫療保健系統的負擔。隨著快速、分散檢測的需求不斷成長，POC感染疾病診斷對於全球健康將變得越來越重要，在更好的疾病管理、更快的疫情應對以及更有效的感染疾病控制方面開始發揮作用。

哪些技術進步正在推動照護現場感染疾病診斷的發展和廣泛使用？

技術進步顯著提高了照護現場感染疾病診斷的準確性、速度和多功能性，使其更加有效和廣泛適用。該領域最具創新性的創新之一是分子 POC 診斷的開發，該診斷使用聚合酵素鏈鎖反應(PCR) 和等溫擴增等技術在基因層面上檢測病原體。分子診斷方法靈敏且特異，甚至可以檢測患者檢體中低水平的病原體。分子診斷平台的小型化和實驗室晶片技術的整合使得在照護端進行複雜的分子測試成為可能，其結果與中心實驗室獲得的結果相當。這些進步擴大了分子 POC 診斷的用途，以檢測多種病原體，包括細菌、病毒和真菌，並使得多重檢測能夠從單一樣本同時識別多種感染疾病。

另一項重要的技術進步是快速抗原和抗體測試的發展，它可以提供即時結果來檢測活動性感染疾病或病原體暴露史。側向層析檢測（LFA）是一種常見的快速抗原檢測，廣泛用於檢測COVID-19、流感、瘧疾和HIV等感染疾病。這些測試易於使用、便攜，並在幾分鐘內提供結果，非常適合在臨床和非臨床環境中使用。側流技術的最新創新，例如增強的訊號檢測和奈米顆粒標籤的使用，提高了這些測試的靈敏度和可靠性，支持它們在疾病監測和社區篩檢計畫中的廣泛採用。此外，採用基於智慧型手機的讀出系統的下一代側流分析的開發正在實現數位分析和即時資料共用，從而增加了 POC 診斷與數位健康平台的整合。

數位科技與人工智慧（AI）的融合進一步加速了照護現場感染疾病診斷的發展。數位 POC 診斷具有連接功能，可將測試結果發送到電子健康記錄(EHR)、雲端基礎的平台和行動應用程式，從而實現遠端監控和遠端健康諮詢。人工智慧和機器學習演算法的使用增強了對測試結果的解釋，減少了人為錯誤的可能性，並為臨床醫生提供了可行的見解。使用人工智慧的 POC 診斷也用於開發疾病發生的預測模型並最佳化現場診斷工作流程。數位科技與人工智慧的結合可以實現更有效率的資料收集、分析和報告，使POC診斷成為公共衛生監測和流行病學研究的強大工具。隨著技術的進步，POC感染疾病的診斷預計將變得更加準確、更容易獲得，並整合到更廣泛的醫療保健系統中，從而實現更有效的疾病管理和控制。

市場動態與監理標準如何形塑照護現場感染疾病診斷市場？

照護現場感染疾病診斷市場是由影響產品開拓、採用和商業化的市場動態、監管標準和醫療保健趨勢之間的複雜相互作用形成的。市場促進因素之一是已開發國家和新興國家感染疾病的日益流行，這推動了對快速且易於使用的檢測解決方案的需求。愛滋病毒、結核病、肝炎和瘧疾等感染疾病繼續對全球健康構成重大挑戰，特別是在診斷基礎設施有限的低收入和中等收入國家。最近的 COVID-19 大流行進一步凸顯了快速、廣泛檢測的必要性，並凸顯了 POC 診斷在疫情應對和公共衛生管理中的關鍵作用。隨著世界各地的醫療保健系統努力改善感染疾病的檢測和控制，對能夠快速有效地提供可靠結果的 POC 診斷的需求預計將會增加。

監管標準和合規要求在塑造照護現場感染疾病診斷市場方面也發揮著重要作用。監管機構，例如美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA) 和其他地區機構，對診斷測試的開發、核准和商業化實施嚴格的規定，以確保其安全性、有效性和可靠性。遵守這些法規對於製造商進入市場並維持醫療保健提供者和患者的信任至關重要。監管環境正在不斷發展，以適應 POC 診斷的快速發展和部署，特別是為了應對突發公共衛生事件。例如，FDA 的緊急使用核准(EUA) 流程在 COVID-19 大流行期間得到了廣泛使用，以促進 SARS-CoV-2 快速檢測的快速核准，並促進在醫療保健和社區環境中的快速分發和分發。其他地區正在考慮類似的監管途徑，以支持新興感染疾病的 POC 診斷的開發。

製造商之間的競爭、技術創新和醫療保健報銷政策等市場動態也正在影響照護現場感染疾病診斷市場。競爭格局的特點是成熟的診斷製造商和創新新興企業，每個製造商都在努力開發新穎的 POC 測試解決方案，以提供卓越的性能、易用性和經濟性。每家公司都透過產品創新、策略夥伴關係以及提供全面診斷解決方案（包括儀器、試劑和數位健康整合）的能力來使自己脫穎而出。價格壓力很大，尤其是在成本敏感的市場，推動了對低成本 POC 測試的需求，這些測試可以在不影響品質的情況下提供高性能。此外，醫療保健報銷政策和付款人的承保範圍決定也會影響 POC 測試產品的採用，因為 POC 測試產品的可用性和可負擔性通常由報銷決定。報銷環境因地區而異，並受到測試的臨床效用、替代診斷選項的可用性以及整體醫療保健預算等因素的影響。對於在未滿足的關鍵字市場中經營的公司來說，利用這些市場動態和監管標準至關重要，因為他們尋求擴大其影響力並滿足全球患者和醫療保健提供者未滿足的診斷需求。

推動照護現場感染疾病診斷市場擴張的關鍵成長要素是什麼？

全球照護現場感染疾病診斷市場的成長是由幾個關鍵因素推動的，包括感染疾病病率的增加、對快速和分散檢測解決方案的需求不斷成長以及診斷技術的進步。關鍵的成長要素之一是全球感染疾病率的上升，對支持早期檢測和及時治療決策的診斷工具產生了巨大需求。愛滋病毒、結核病、肝炎和性行為感染感染（STI）等感染疾病仍然是重大的公共衛生挑戰，特別是在低收入和中等收入國家。 POC 診斷透過在農村診所、社區健康中心和居家醫療機構等分散環境中實現快速、準確的檢測，在應對這些挑戰方面發揮著重要作用。 POC 診斷可以在照護端快速提供結果，改善患者接受檢測的機會，實現早期診斷並立即開始治療。

另一個主要的成長要素是人們越來越關注快速且分散的檢測解決方案，特別是在 COVID-19 大流行等全球突發衛生事件期間。這場大流行凸顯了可擴展且易於使用的診斷解決方案對於限制疾病傳播和管理公共衛生的重要性。 POC 診斷不需要複雜的測試基礎設施並提供即時結果，已成為對抗 COVID-19 和其他新興感染疾病的重要工具。隨著醫療保健系統尋求建立更具彈性和快速的診斷能力，在大流行期間獲得的經驗預計將有助於繼續採用其他感染疾病的 POC 診斷。對家庭測試和自我測試選項不斷成長的需求也促進了市場成長，因為這些測試非常方便，並且支援非傳統醫療保健環境中的疾病管理。

診斷技術的進步進一步推動了照護現場感染疾病診斷市場的擴張。分子 POC 平台、數位診斷和連接功能等創新正在推動測試的開發，提供更高的靈敏度、特異性和易用性。分子 POC 平台利用 PCR 和等溫擴增等技術，提供高度準確的結果，可檢測從細菌、病毒到真菌等多種病原體。借助基於智慧型手機的讀取系統和雲端連接的數位診斷可實現遠端監控並與遠端醫療平台整合，支援更全面的疾病管理和監測。可以從單一樣本同時檢測多種病原體的多重 POC 測試的發展也擴展了 POC 診斷的能力，使其更加通用和高效。

最後，對公共衛生措施的日益關注和新興市場診斷基礎設施的擴大正在促進照護現場感染疾病診斷市場的成長。在亞太地區、非洲和拉丁美洲等感染疾病負擔較高且實驗室檢測機會有限的地區，POC 診斷提供了改善疾病檢測和控制的解決方案。各國政府、非營利組織和國際衛生組織正在投資診斷基礎設施和以地區為基礎的檢測項目，以增加獲得醫療保健的機會並減輕疾病負擔。在這些地區，負擔得起的 POC 診斷變得越來越容易獲得，支持廣泛的檢測和改善的醫療保健結果。感染疾病，全球照護現場感染呈上升趨勢。進步、應用範圍擴大以及對快速和分散測試解決方案的日益重視推動了持續成長。

受訪企業範例（共38家）

• AccuBioTech Co., Ltd.
• Agilent Technologies, Inc.
• BioFire Diagnostics LLC
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Cardinal Health, Inc.
• Cepheid
• Chembio Diagnostic Systems, Inc.
• Danaher Corporation
• EKF Diagnostics Holdings PLC

目錄

第1章調查方法

第 2 章執行摘要

• 市場概況
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 比賽

Global Point-of-Care Infectious Disease Diagnostics Market to Reach US$5.3 Billion by 2030

The global market for Point-of-Care Infectious Disease Diagnostics estimated at US$2.6 Billion in the year 2023, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2023-2030. Lateral Flow Immunoassay Technique, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Flow-through Test Technique segment is estimated at 10.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$711.3 Million While China is Forecast to Grow at 14.8% CAGR

The Point-of-Care Infectious Disease Diagnostics market in the U.S. is estimated at US$711.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Point-of-Care Infectious Disease Diagnostics Market - Key Trends & Drivers Summarized

Why Are Point-of-Care Infectious Disease Diagnostics Transforming Healthcare Delivery and Patient Outcomes?

Point-of-care (POC) infectious disease diagnostics are revolutionizing healthcare by enabling rapid, accurate, and decentralized testing of infectious diseases at or near the site of patient care. These diagnostics include a range of tests, such as lateral flow assays, rapid antigen tests, molecular diagnostic assays, and immunoassays, which can be performed outside traditional laboratory settings, providing healthcare providers with critical information for timely clinical decision-making. Unlike conventional diagnostic methods that require centralized laboratories, specialized equipment, and longer turnaround times, POC diagnostics deliver results within minutes to hours, allowing for immediate diagnosis and initiation of treatment. This rapid testing capability is particularly vital in the management of infectious diseases such as HIV, tuberculosis, influenza, and sexually transmitted infections (STIs), where early detection and prompt treatment are crucial to controlling disease spread and improving patient outcomes.

The growing adoption of POC infectious disease diagnostics is driven by their ability to increase access to testing, particularly in remote, resource-limited, and underserved areas. These diagnostics eliminate the need for complex laboratory infrastructure, making it possible to perform testing in rural clinics, community health centers, and even in patients’ homes. This accessibility is crucial for addressing global health challenges, especially in low- and middle-income countries where healthcare resources are limited and the burden of infectious diseases is high. Moreover, the convenience and ease of use of POC diagnostics enhance patient compliance and reduce the need for follow-up visits, supporting more efficient healthcare delivery and reducing the burden on healthcare systems. As the demand for rapid and decentralized testing continues to grow, POC infectious disease diagnostics are poised to play an increasingly important role in global health, enabling better disease management, faster outbreak response, and more effective control of infectious diseases.

What Technological Advancements Are Driving the Evolution and Adoption of Point-of-Care Infectious Disease Diagnostics?

Technological advancements are significantly enhancing the accuracy, speed, and versatility of point-of-care infectious disease diagnostics, making them more effective and widely applicable. One of the most transformative innovations in this field is the development of molecular POC diagnostics, which utilize techniques such as polymerase chain reaction (PCR) and isothermal amplification to detect pathogens at the genetic level. Molecular diagnostics offer high sensitivity and specificity, enabling the detection of even low levels of pathogens in patient samples. The miniaturization of molecular diagnostic platforms and the integration of lab-on-a-chip technologies are making it possible to perform complex molecular tests at the point of care, providing results that are comparable to those obtained in centralized laboratories. These advancements are expanding the use of molecular POC diagnostics for detecting a wide range of pathogens, including bacteria, viruses, and fungi, and are enabling multiplex testing to identify multiple infections simultaneously from a single sample.

Another significant technological advancement is the development of rapid antigen and antibody tests, which provide immediate results for detecting active infections or prior exposure to pathogens. Lateral flow assays (LFAs), a common type of rapid antigen test, are widely used for detecting infectious diseases such as COVID-19, influenza, malaria, and HIV. These tests are designed to be user-friendly, portable, and capable of delivering results within minutes, making them ideal for use in both clinical and non-clinical settings. Recent innovations in lateral flow technology, such as enhanced signal detection and the use of nanoparticle labels, are improving the sensitivity and reliability of these tests, supporting their broader adoption in disease surveillance and community screening programs. Additionally, the development of next-generation lateral flow assays with smartphone-based readout systems is enabling digital analysis and real-time data sharing, enhancing the integration of POC diagnostics into digital health platforms.

The integration of digital technologies and artificial intelligence (AI) is further driving the evolution of point-of-care infectious disease diagnostics. Digital POC diagnostics are being developed with connectivity features that allow them to transmit test results to electronic health records (EHRs), cloud-based platforms, or mobile apps, enabling remote monitoring and telehealth consultations. The use of AI and machine learning algorithms is enhancing the interpretation of test results, reducing the potential for human error, and providing actionable insights for clinicians. AI-driven POC diagnostics are also being used to develop predictive models for disease outbreaks and to optimize diagnostic workflows in field settings. The combination of digital technologies and AI is enabling more efficient data collection, analysis, and reporting, making POC diagnostics powerful tools for public health monitoring and epidemiological research. As technology continues to advance, POC infectious disease diagnostics are expected to become even more accurate, accessible, and integrated with broader healthcare systems, supporting more effective disease management and control.

How Are Market Dynamics and Regulatory Standards Shaping the Point-of-Care Infectious Disease Diagnostics Market?

The point-of-care infectious disease diagnostics market is shaped by a complex interplay of market dynamics, regulatory standards, and healthcare trends that are influencing product development, adoption, and commercialization. One of the primary market drivers is the increasing prevalence of infectious diseases, both in developed and developing regions, which is creating a growing demand for rapid and accessible testing solutions. Infectious diseases such as HIV, tuberculosis, hepatitis, and malaria continue to pose significant health challenges globally, particularly in low- and middle-income countries where diagnostic infrastructure is limited. The recent COVID-19 pandemic has further underscored the need for rapid and widespread testing, highlighting the critical role of POC diagnostics in outbreak response and public health management. As healthcare systems around the world strive to improve infectious disease detection and control, the demand for POC diagnostics that can deliver reliable results quickly and efficiently is expected to rise.

Regulatory standards and compliance requirements are also playing a crucial role in shaping the point-of-care infectious disease diagnostics market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional bodies have established stringent guidelines for the development, approval, and commercialization of diagnostic tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to accommodate the rapid development and deployment of POC diagnostics, particularly in response to public health emergencies. For example, the FDA’s Emergency Use Authorization (EUA) process, which was widely used during the COVID-19 pandemic, facilitated the expedited approval of rapid tests for SARS-CoV-2, enabling their rapid distribution and use in healthcare and community settings. Similar regulatory pathways are being explored in other regions to support the development of POC diagnostics for emerging infectious diseases.

Market dynamics such as competition among manufacturers, technological innovation, and healthcare reimbursement policies are also influencing the point-of-care infectious disease diagnostics market. The competitive landscape is characterized by the presence of established diagnostic companies and innovative startups, each striving to develop novel POC testing solutions that offer superior performance, ease of use, and affordability. Companies are differentiating themselves through product innovation, strategic partnerships, and the ability to provide comprehensive diagnostic solutions that include devices, reagents, and digital health integrations. Pricing pressures, particularly in cost-sensitive markets, are driving the demand for low-cost POC tests that offer high performance without compromising quality. Additionally, healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of POC diagnostics, as reimbursement often determines the accessibility and affordability of these products. Reimbursement environments vary significantly across regions and are influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the point-of-care infectious disease diagnostics market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers worldwide.

What Are the Key Growth Drivers Fueling the Expansion of the Point-of-Care Infectious Disease Diagnostics Market?

The growth in the global point-of-care infectious disease diagnostics market is driven by several key factors, including the increasing prevalence of infectious diseases, the growing demand for rapid and decentralized testing solutions, and advancements in diagnostic technologies. One of the primary growth drivers is the rising incidence of infectious diseases worldwide, which is creating a significant need for diagnostic tools that can provide early detection and support timely treatment decisions. Infectious diseases such as HIV, tuberculosis, hepatitis, and sexually transmitted infections (STIs) continue to be major public health challenges, particularly in low- and middle-income countries. Point-of-care diagnostics are playing a critical role in addressing these challenges by enabling rapid and accurate testing in decentralized settings, such as rural clinics, community health centers, and home care environments. The ability of POC diagnostics to deliver results quickly and at the site of care is enhancing patient access to testing, supporting early diagnosis, and enabling immediate initiation of treatment, which is crucial for improving patient outcomes and reducing disease transmission.

Another significant growth driver is the increasing focus on rapid and decentralized testing solutions, particularly in the context of global health emergencies such as the COVID-19 pandemic. The pandemic has highlighted the importance of scalable and accessible diagnostic solutions for controlling disease spread and managing public health. POC diagnostics, with their ability to provide real-time results without the need for complex laboratory infrastructure, have become essential tools in the fight against COVID-19 and other emerging infectious diseases. The experience gained during the pandemic is expected to drive the continued adoption of POC diagnostics for other infectious diseases, as healthcare systems seek to build more resilient and responsive diagnostic capabilities. The growing demand for at-home and self-testing options is also contributing to market growth, as these tests offer convenience and support disease management in non-traditional healthcare settings.

Advancements in diagnostic technologies are further fueling the expansion of the point-of-care infectious disease diagnostics market. Innovations such as molecular POC platforms, digital diagnostics, and connectivity features are enabling the development of tests that offer higher sensitivity, specificity, and ease of use. Molecular POC platforms, which utilize techniques such as PCR and isothermal amplification, are providing highly accurate results for detecting a wide range of pathogens, from bacteria and viruses to fungi. Digital diagnostics with smartphone-based readout systems and cloud connectivity are enabling remote monitoring and integration with telehealth platforms, supporting more comprehensive disease management and surveillance. The development of multiplex POC tests, which can detect multiple pathogens simultaneously from a single sample, is also expanding the capabilities of POC diagnostics, making them more versatile and efficient.

Lastly, the increasing focus on public health initiatives and the expansion of diagnostic infrastructure in emerging markets are contributing to the growth of the point-of-care infectious disease diagnostics market. In regions such as Asia-Pacific, Africa, and Latin America, where the burden of infectious diseases is high and access to laboratory testing is limited, POC diagnostics are providing a solution for improving disease detection and control. Governments, non-profit organizations, and global health agencies are investing in diagnostic infrastructure and community-based testing programs to enhance access to care and reduce disease burden. The increasing availability of affordable POC diagnostics in these regions is supporting the broader adoption of testing and improving health outcomes. As demand from key sectors such as public health, primary care, and home healthcare continues to rise, and as manufacturers innovate to meet evolving healthcare needs, the global point-of-care infectious disease diagnostics market is expected to witness sustained growth, driven by advancements in technology, expanding applications, and the increasing emphasis on rapid and decentralized testing solutions.

Select Competitors (Total 38 Featured) -

• AccuBioTech Co., Ltd.
• Agilent Technologies, Inc.
• BioFire Diagnostics LLC
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Cardinal Health, Inc.
• Cepheid
• Chembio Diagnostic Systems, Inc.
• Danaher Corporation
• EKF Diagnostics Holdings PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Point-of-Care Infectious Disease Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Focus on Early Diagnosis and Disease Prevention Drives Growth in Point-of-Care Infectious Disease Diagnostics Market
  • Increasing Adoption of Rapid Diagnostic Tests Expands Addressable Market for Point-of-Care Solutions
  • Case Overview: Growth in Global Infectious Disease Burden Bodes Well for Point-of-Care Diagnostics Market Expansion
  • Focus on Reducing Diagnostic Turnaround Time and Enhancing Patient Outcomes Strengthens Business Case for Market Adoption
  • Case Overview: Growth in Adoption of Point-of-Care Testing in Emergency and Critical Care Settings Expands Market Reach
  • Rising Focus on Infectious Disease Surveillance and Epidemiology Expands Market Opportunities
  • Increasing Use of Point-of-Care Diagnostics in Home Healthcare and Self-Testing Expands Market Scope
  • Case Overview: Growth in Digital Health Platforms and Telemedicine Drives Demand for Point-of-Care Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Point-of-Care Infectious Disease Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Lateral Flow Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Lateral Flow Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Lateral Flow Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Flow-through Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Flow-through Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Flow-through Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Agglutination Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Agglutination Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Agglutination Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Home End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Home End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Home End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Assisted Living Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Assisted Living Healthcare Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• JAPAN
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• CHINA
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• EUROPE
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• FRANCE
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: France 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: France 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• GERMANY
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Germany 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Italy 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: UK 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Spain 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Russia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Rest of Europe 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Australia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• INDIA
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 125: India Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: India 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 128: India Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: India 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: South Korea 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Argentina 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Brazil 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Mexico 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Rest of Latin America 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Iran 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Israel 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Saudi Arabia 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: UAE 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Rest of Middle East 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030
• AFRICA
  • Point-of-Care Infectious Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Point-of-Care Infectious Disease Diagnostics by Technique - Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by Technique - Percentage Breakdown of Value Sales for Lateral Flow Immunoassay, Flow-through Test, Molecular Diagnostics, Agglutination Test and Other Techniques for the Years 2014, 2024 & 2030
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Point-of-Care Infectious Disease Diagnostics by End-Use - Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Africa 16-Year Perspective for Point-of-Care Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Clinics End-Use, Hospitals End-Use, Home End-Use and Assisted Living Healthcare Facilities End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION